



Director, Prostate Program: **Riccardo Valdagni, MD, PhD**
20133 Milan (Italy) – via Venezian, 1

Riccardo Valdagni, MD, PhD

Work address: Fondazione IRCCS Istituto Nazionale dei Tumori, Via G. Venezian, 1 20133 Milan, (IT)

Education and Training

1979 - Degree in Medicine and Surgery, Università di Bologna (IT)

1984 - Master of Science in Radiation Oncology, Università di Padoa (IT)

1985 and 1987 Research Scholar, Radiation Oncology, Stanford University Medical College - Stanford, CA (US)

1997 - Psychotherapist, Il Ruolo Terapeutico, Milan (IT)

2001 - Psychoanalysis, Il Ruolo Terapeutico, Milan (IT)

Current position

Since February 2016, Associate Professor, Department of Oncology and Hemato-oncology, Università degli Studi di Milano (IT)

Since 2015, President, Italian Society for Urologic Oncology (SIUrO)

Since 2011, Director, Radiation Oncology 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (IT)

The clinical research of the Radiotherapy Oncology 1 Unit is aimed at optimizing radiotherapeutic treatments for patients with breast cancer, genitourinary cancers, gastrointestinal cancers, lung cancers, bone and soft tissue sarcomas, lymphomas, and pediatric cancers treated in our Institution according to national and international protocols. The multidisciplinary management represents a priority to deliver high quality therapies to cancer patients. Therefore, all the Staff Members are actively involved in multidisciplinary case discussions and clinics for cancer patients at all stages, from diagnosis as well as during follow-up. In close collaboration with the Medical Physics Unit, particular attention and efforts are dedicated to validate the new available technologies in every specific clinical setting.

The Radiation Oncology 1 is also proactive in preclinical and translational research. Topics of interest are the prediction of acute and late rectal toxicity after high dose prostate cancer radiotherapy, the correlation between plasma levels of inflammatory markers and radiation induced acute and late toxicity, the prediction of erectile dysfunction and genito-urinary toxicity following prostate cancer radiotherapy, the quality of life in patients who underwent prostate cancer radiotherapy (DUE-01 protocol), and, in collaboration with the Department of Experimental Oncology, the validation of a vaccine combination (survivin peptides and IMP321) for hormone-naïve or refractory prostate cancer patients with biochemical recurrence.

Since 2008, Prostate Cancer Programme Coordinator, European School of Oncology

Started in 2008 after the success of the Inside Track Conference: “Predictive Modelling in Prostate Cancer”, the aims are:

1. To contribute culturally to the fight against prostate cancer
2. To organise focused educational events
3. To support the advocacy group “Europa Uomo - The European Prostate Coalition
4. To address the issue of the multidisciplinary management of prostate cancer

Core Topics are:



Director, Prostate Program: Riccardo Valdagni, MD, PhD
20133 Milan (Italy) – via Venezian, 1

1. Predictive modelling and personalized medicine
2. Active surveillance
3. Interdisciplinary and multiprofessional management of prostate cancer patients and promotion of Prostate Cancer Units

Since 2004, Director, Prostate Cancer Program, Scientific Director's Office, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (IT)

The Prostate Cancer Programme is a disease-focused multidisciplinary translational programme that combines the know how of the preclinical research to the clinical practice, with a bench to bed approach.

- More than 20 clinical and preclinical research projects currently running
- Institution-adapted diagnostic and therapeutic guidelines in prostate cancer, 2006 (first ed) and 2012 (second ed)
- Multidisciplinary Clinic for prostate cancer patients, since 2005
- Discussion of Clinical Cases, since 2005
- Holistic care and individualized therapeutic approach to prostate cancer patients
- Dedicated psychologists counseling and support to patients and their significant others after diagnosis, in the decision making phase, during and after therapy (individual, family and group support)
- Active surveillance, since 2005
- Educational CME activities: monthly Seminars, weekly clinical case rounds
- Prostate Cancer Unit established in 2009
- Fund raising

Previous positions

Head, Division of Radiation Oncology, Casa di Cura San Pio X, Milan, IT, 1988-2003

Division of Radiation Oncology, Ospedale Santa Chiara, Trento, IT, 1987-1984

Consultant in Biomedical Physics, Istituto per la ricerca scientifica e tecnologica (ITC-irst), Istituto Trentino di Cultura, Trento, 1988 – 1993

Scientific Consultant, Biophysics Laboratory, Università di Trento, 1982 - 1984



Director, Prostate Program: Riccardo Valdagni, MD, PhD
20133 Milan (Italy) – via Venezian, 1

Working Groups and other experiences

- Member, Scientific Committee, Fondazione Centro Nazionale Adroterapia Oncologica (CNAO), Pavia, since 2014
- Member, “MRI in Active Surveillance for Prostate Cancer” Task Force, European School of Oncology (ESO), since 2014
- Member, Task Force “Quality of Life of Patients on Active Surveillance”, European School of Oncology (ESO), since 2014
- Coordinator, “Prostate Cancer Unit Initiative in Europe”, European School of Oncology (ESO), since 2012
- Member, Working Group, “Validating predictive models of radiotherapy toxicity to improve quality-of-life and reduce side-effects in cancer survivors (REQUIRE)” project, since 2014
- Member, Working Group, “Global Action Plan 3 on Active Surveillance”, Movember Foundation, since 2014
- Member, Clinical Working Group Europa Uomo Europa, “Improving prostate cancer care across Europe – a call to action”, White Paper, 2013
- Member, Scientific Committee, “PEACE2 - A randomized Phase III, factorial design, of cabazitaxel and pelvic radiotherapy in patients with localized prostate cancer and high-risk features of relapse” protocol, since 2013
- Member, Working Group, “ Guidelines on Prostate Cancer”, European Society of Medical Oncology (ESMO), 2013
- Member, Working Group “Predictive models of genito-urinary and sexual dysfunctions after high dose Radiotherapy for prostate cancer (DUE-01)”, since 2010
- Member, Steering Committee of Prostate cancer Research International: Active Surveillance (PRIAS), since 2010
- Coordinator, SIUrO PRIAS ITA active surveillance multicenter prospective trial, since 2009
- Member, Scientific Board, Europa Uomo Italia Onlus, since 2009
- Head, Advisory Board, ProAdamo Onlus Foundation, Milan, since 2009
- Member, Steering Committee, Europa Uomo Italia Onlus, 2005-2009
- Scientific Director, Regione Lombardia ROL Project on Prostate and Urologic Cancers, since 2009
- Member, Scientific Board, Europa Uomo Europa, since 2008
- Member, Consiglio Nazionale delle Ricerche (CNR) Group “Guidelines in prostate cancer”, since 2005
- Founder and head of AIRO Group “Prostate cancer irradiation”, 2005
- Head, Istituto Superiore di Sanità (ISS) Subgroup “Quality Assurance indicators in prostate cancer irradiation”, 2000-2004
- Member, ISS Group “Indicators on quality in radiotherapy”, 2000-2004
- Head, “Standard of reference in breast irradiation” Group of the Italian Association for Radiation Oncology (AIRO), 1996-1997
- Member, ISS Group “Quality Controls in radiotherapy”, 1998
- Member, ISS Group "Quality Assurance in conformal radiotherapy", 1993-2004
- Member, ISS Group “Continuous improvement on quality in radiotherapy”, 2000-2004
- Project Leader, “Prostate Cancer” Project, Alleanza contro il Cancro, 2004-2006



Director, Prostate Program: Riccardo Valdagni, MD, PhD
20133 Milan (Italy) – via Venezian, 1

Member, Editorial Board, Critical Reviews in Oncology/Hematology, since 2013
Reviewer, International Journal of Cancer, since 2011
Reviewer, European Urology, since 2008
Reviewer, Radiotherapy and Oncology, since 1991
Reviewer, Tumori Journal, since 1997
Reviewer, International Journal of Radiation Oncology, Biology and Physics, since 1988
Member, Editorial Board, International Journal of Radiation Oncology, Biology and Physics, 1989 - 2011
Reviewer, International Journal of Hyperthermia, 1984 - 2000

Scientific societies

Associazione Italiana di Oncologia Medica (AIOM)
Associazione Italiana di Radioterapia Oncologica (AIRO)
American Society of Clinical Oncology (ASCO)
Associazione Urologi Italiani (AURO)
American Society for Therapeutic Radiology and Oncology (ASTRO)
European Association of Urology (EAU)
European Society for Therapeutic Radiology and Oncology (ESTRO)
Società Italiana di Urologia Oncologica (SIUrO)
Società Italiana di Urologia (SIU)

Prof. Riccardo Valdagni